Cost-effectiveness analysis comparing single-pill combination of perindopril/amlodipine/indapamide to the free equivalent combination in patients with hypertension from an Italian national health system perspective.
Pierre LevyTobiasz LemańskiCatriona CrossanAnna LefebvreJean-Baptiste BrièreLuca Degli EspostiZeba M KhanPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
The findings indicate that a perindopril/amlodipine/indapamide SPC is a cost-saving treatment option for hypertension in Italy, compared to its FEC.